Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Laparoscopic Colorectal Surgeries
Conditions
Laparoscopic Colorectal Surgeries
Trial Timeline
May 30, 2019 → Jul 1, 2022
NCT ID
NCT03910998About Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2
Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 is a approved stage product being developed by Merck for Laparoscopic Colorectal Surgeries. The current trial status is unknown. This product is registered under clinical trial identifier NCT03910998. Target conditions include Laparoscopic Colorectal Surgeries.
What happened to similar drugs?
2 of 5 similar drugs in Laparoscopic Colorectal Surgeries were approved
Approved (2) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03910998 | Approved | UNKNOWN |
Competing Products
7 competing products in Laparoscopic Colorectal Surgeries
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 35 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 35 |
| Rocuronium + Rocuronium | Merck | Approved | 43 |
| etoricoxib 120 mg | Merck | Approved | 43 |
| placebo + valdecoxib + valdecoxib | Pfizer | Phase 3 | 40 |
| N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo | Alkermes | Phase 3 | 29 |